middle.news
SomnoMed Advances US Clinical Trial as Q1 Revenue Climbs 13.5%
8:42am on Thursday 30th of October, 2025 AEDT
•
Healthcare
Read Story
SomnoMed Advances US Clinical Trial as Q1 Revenue Climbs 13.5%
8:42am on Thursday 30th of October, 2025 AEDT
Key Points
Q1 FY26 revenue rises 13.5% to $28.7 million
Clayton Sleep Institute confirmed as first US clinical site for Rest Assure study
FDA agrees in principle with Rest Assure study protocol
Europe and North America drive double-digit regional growth
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
SOM
OPEN ARTICLE